Developer docs
API playgroundTry for free, no card

Search company profiles

Praxis Precision Medicines

Full company profile

uuid000093b

Namestring
Praxis Precision Medicines
Legal namestring
Praxis Precision Medicines, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Praxis Precision Medicines is a fully integrated, clinical-to-commercial stage CNS precision neuroscience biopharmaceutical company founded in 2015 and headquartered in Boston, Massachusetts, trading on NASDAQ under the ticker PRAX. The company translates insights from human genetic epilepsies into therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, operating two proprietary discovery platforms — Cerebrum (a small molecule platform applying computational and experimental tools to develop orally available precision modulators of neuronal excitability, including T-type calcium channel and sodium channel modulators) and Solidus (an antisense oligonucleotide engine anchored on proprietary computational methodology producing gapmer and splice-switching ASOs). Its pipeline spans movement disorders and epilepsy with four late-stage assets: ulixacaltamide for essential tremor (NDA accepted, PDUFA January 29, 2027), relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (NDA accepted under Priority Review, PDUFA September 27, 2026), vormatrigine for focal onset seizures (Phase 2/3, POWER1 endpoint not met), and elsunersen for early onset SCN2A DEE (Breakthrough Therapy Designation granted June 2026).

Praxis is pre-commercial with zero product revenue as of Q1 2026, operating a capital-intensive clinical development business funded through repeated public equity offerings totaling over $1.6 billion since IPO, with approximately $1.4 billion in cash and investments funding operations into 2028. The go-to-market model upon FDA approval will deploy specialty pharmacy distribution and field sales targeting specialized neurology prescribers and rare disease patients across two simultaneous launches — ulixacaltamide into a large essential tremor patient population of approximately 7 million in the United States, and relutrigine into the ultra-rare SCN2A/SCN8A-DEE population. Management has reinforced commercial readiness through January 2026 leadership restructuring, including the promotion of Megan Sniecinski to Chief Operating Officer and the addition of former Pfizer CEO Jeffrey Kindler and former Vertex COO Stuart Arbuckle to the board.

The company's revenue model is presently non-operational, with future economics dependent on FDA approvals, pricing, and physician adoption across indications with combined peak revenue potential exceeding $20 billion based on analyst and management estimates. Stakeholder value is currently driven by regulatory and clinical milestones — multiple Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from FDA, plus EMA PRIME designation for elsunersen — rather than recurring product sales.

Short descriptiontext

Praxis Precision Medicines is a clinical-stage CNS biopharmaceutical company developing precision small molecule and antisense oligonucleotide therapies for genetic epilepsies and essential tremor, with two NDAs under FDA review and combined peak revenue potential exceeding $20 billion.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision neuroscience, CNS therapeutics, antisense oligonucleotide therapy, epilepsy treatment drugs, ion channel modulators
Industry4 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
CNS Therapeutics / Precision Neuroscience Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-commercial stage biopharmaceutical company with no current revenue. Planning to launch multiple CNS therapies pending FDA approvals for ulixacaltamide (essential tremor) and relutrigine (DEEs). Four late-stage clinical assets carry projected combined revenue potential exceeding $20 billion.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, including essential tremor, developmental and epileptic encephalopathies, focal onset seizures, and generalized epilepsy. The company leverages two proprietary discovery platforms: Cerebrum (small molecule platform for orally available neuronal excitability modulators) and Solidus (antisense oligonucleotide discovery engine). Late-stage drug candidates include ulixacaltamide for essential tremor, relutrigine for SCN2A/SCN8A-DEEs, vormatrigine for focal epilepsy, and elsunersen for SCN2A-DEE.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 77% sham-adjusted reduction in monthly seizures among pediatric SCN2A-DEE patients (EMBRAVE Part A trial)
+4 more records
Product overview1 text field

Praxis Precision Medicines is a fully integrated CNS precision neuroscience biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company operates two dedicated technology platforms: Cerebrum (small molecule platform) and Solidus (antisense oligonucleotide platform). The portfolio spans movement disorders and epilepsy, including ulixacaltamide for essential tremor (Phase 3 complete, NDA accepted with January 2027 PDUFA), relutrigine for SCN2A/8A DEEs (Phase 2/3, NDA accepted with September 2026 PDUFA under Priority Review), vormatrigine for focal onset seizures (Phase 2/3), and elsunersen for early onset SCN2A DEE (Phase 1/2). Multiple candidates have received Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from FDA and EMA.

Product and service9 records
1Ulixacaltamide
CategoryDrug Candidate - Small Molecule
Description

Selective T-type calcium channel modulator in development as an oral precision therapy for essential tremor in adults; received FDA Breakthrough Therapy Designation and NDA acceptance with PDUFA target action date of January 29, 2027.

2Relutrigine
CategoryDrug Candidate - Small Molecule
Description

Sodium channel functional state modulator for SCN2A- and SCN8A-DEEs and broad developmental and epileptic encephalopathies; received FDA Breakthrough Therapy Designation, Orphan Drug Designation, and Priority Review with PDUFA target action date September 27, 2026.

3Vormatrigine
CategoryDrug Candidate - Small Molecule
Description

Sodium channel functional state modulator for focal onset seizures and generalized epilepsy; being evaluated in POWER1 and POWER2 Phase 2/3 trials.

4Elsunersen (PRAX-222)
CategoryDrug Candidate - Antisense Oligonucleotide
Description

Gapmer antisense oligonucleotide for early onset SCN2A developmental and epileptic encephalopathy; received FDA Orphan Drug Designation, Rare Pediatric Disease Designation, and Breakthrough Therapy Designation, plus EMA Orphan Drug Designation and Priority Medicines (PRIME) designation.

5PRAX-020
CategoryDrug Candidate - Small Molecule
Description

KCNT1 specific inhibitor small molecule for KCNT1-related conditions including genetic epilepsies.

6PRAX-080
CategoryDrug Candidate - Antisense Oligonucleotide
Description

Gapmer antisense oligonucleotide for PCDH19-related conditions.

7PRAX-090
CategoryDrug Candidate - Antisense Oligonucleotide
Description

Splice switching antisense oligonucleotide for SYNGAP1-related conditions.

8PRAX-100
CategoryDrug Candidate - Antisense Oligonucleotide
Description

Antisense oligonucleotide for SCN2A Autism with undisclosed mechanism.

9PRAX-050
CategoryDrug Candidate - Small Molecule
Description

Movement disorders program with undisclosed mechanism.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-02
Description

Expanded partnership with SEQSTER to accelerate clinical trials and data collection in CNS disorders. The collaboration builds on early success in Praxis's Essential3 Program for Essential Tremor, utilizing SEQSTER's 1-Click DataLake technology to expedite CNS disorder trials.

Strategic tierMinorTypeOthers
Description

Praxis Precision Medicines participated as a speaker and panelist at SK pharmteco's Innovations in Pharmaceutical Manufacturing symposium in Cambridge, Massachusetts, discussing topics including synthetic biology, yeast metabolic engineering, small-molecule scale-up, and stereochemical control.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CNS biopharmaceutical company developing therapies for neurological and psychiatric disorders. Most comparable to Praxis given its focus on CNS innovation, late-stage CNS pipeline, and similar pre-commercial profile with a breakthrough-designated asset.

TypeDirect peer
Description

Specializes in therapeutics for rare seizure disorders, including a recently approved product for CDKL5 deficiency disorder. Directly comparable to Praxis's SCN2A/SCN8A DEE franchise given its rare pediatric epilepsy focus and similar regulatory pathway strategy.

TypeDirect peer
Description

Rare disease biopharmaceutical company with multiple approved products and a CNS franchise. Highly comparable given shared leadership pedigree (Marcio Souza was previously COO), rare disease commercial infrastructure, and small-molecule platform approach.

TypeDirect peer
Description

Clinical-stage company developing antisense oligonucleotide medicines for genetic diseases, including SCN1A-related Dravet syndrome. Directly comparable given shared focus on ion channelopathies and the Solidus ASO platform approach to CNS genetic epilepsies.

TypeBroad incumbent
Description

Global biopharmaceutical company with a major CNS and epilepsy franchise including multiple approved anti-seizure medications. Comparable as a broad incumbent in the CNS/epilepsy space that Praxis's relutrigine and vormatrigine will compete against commercially.

TypeBroad incumbent
Description

Specialty biopharmaceutical company with a significant CNS/epilepsy portfolio including recently acquired products for rare epilepsies. Comparable given its specialty pharma commercial model focused on CNS and rare neurological disorders.

TypeBroad incumbent
Description

Major CNS-focused biopharmaceutical company with a portfolio spanning neurology, rare disease, and movement disorders. Comparable as a broad incumbent in CNS with similar strategic emphasis on neurological disease modification.

TypeEmerging player
Description

Clinical-stage genetic disease company with programs across rare disorders. Comparable given its genetically driven drug development approach targeting defined patient populations, similar to Praxis's genetic epilepsy strategy.

TypeBroad incumbent
Description

Established leader in antisense oligonucleotide drug discovery and development with multiple approved products. Comparable as a broader incumbent in the ASO modality that Praxis's Solidus platform competes with in CNS indications.

TypeEmerging player
Description

Clinical-stage genetic medicines company developing oligonucleotide therapies, including programs for CNS disorders such as SCN2A. Directly comparable as an emerging ASO player targeting overlapping CNS genetic epilepsies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Praxis Precision Medicines

CNS Therapeutics / Precision Neuroscience Biopharmaceuticalspraxismedicines.com

Praxis Precision Medicines is a clinical-stage CNS biopharmaceutical company developing precision small molecule and antisense oligonucleotide therapies for genetic epilepsies and essential tremor, with two NDAs under FDA review and combined peak revenue potential exceeding $20 billion.

What Praxis Precision Medicines does

Praxis Precision Medicines is a fully integrated, clinical-to-commercial stage CNS precision neuroscience biopharmaceutical company founded in 2015 and headquartered in Boston, Massachusetts, trading on NASDAQ under the ticker PRAX. The company translates insights from human genetic epilepsies into therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, operating two proprietary discovery platforms — Cerebrum (a small molecule platform applying computational and experimental tools to develop orally available precision modulators of neuronal excitability, including T-type calcium channel and sodium channel modulators) and Solidus (an antisense oligonucleotide engine anchored on proprietary computational methodology producing gapmer and splice-switching ASOs). Its pipeline spans movement disorders and epilepsy with four late-stage assets: ulixacaltamide for essential tremor (NDA accepted, PDUFA January 29, 2027), relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (NDA accepted under Priority Review, PDUFA September 27, 2026), vormatrigine for focal onset seizures (Phase 2/3, POWER1 endpoint not met), and elsunersen for early onset SCN2A DEE (Breakthrough Therapy Designation granted June 2026).

Praxis is pre-commercial with zero product revenue as of Q1 2026, operating a capital-intensive clinical development business funded through repeated public equity offerings totaling over $1.6 billion since IPO, with approximately $1.4 billion in cash and investments funding operations into 2028. The go-to-market model upon FDA approval will deploy specialty pharmacy distribution and field sales targeting specialized neurology prescribers and rare disease patients across two simultaneous launches — ulixacaltamide into a large essential tremor patient population of approximately 7 million in the United States, and relutrigine into the ultra-rare SCN2A/SCN8A-DEE population. Management has reinforced commercial readiness through January 2026 leadership restructuring, including the promotion of Megan Sniecinski to Chief Operating Officer and the addition of former Pfizer CEO Jeffrey Kindler and former Vertex COO Stuart Arbuckle to the board.

The company's revenue model is presently non-operational, with future economics dependent on FDA approvals, pricing, and physician adoption across indications with combined peak revenue potential exceeding $20 billion based on analyst and management estimates. Stakeholder value is currently driven by regulatory and clinical milestones — multiple Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from FDA, plus EMA PRIME designation for elsunersen — rather than recurring product sales.

Praxis Precision Medicines firmographics

Firmographics
Name
Praxis Precision Medicines
Legal name
Praxis Precision Medicines, Inc.
Website
https://praxismedicines.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
Praxis Precision Medicines is a clinical-stage CNS biopharmaceutical company developing precision small molecule and antisense oligonucleotide therapies for genetic epilepsies and essential tremor, with two NDAs under FDA review and combined peak revenue potential exceeding $20 billion.
Ownership category
akta.pro rank

Praxis Precision Medicines industry classification

Industry
Product category
CNS Therapeutics / Precision Neuroscience Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Precision neuroscience
  • CNS therapeutics
  • Antisense oligonucleotide therapy
  • Epilepsy treatment drugs
  • Ion channel modulators

Where Praxis Precision Medicines is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Praxis Precision Medicines business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Pre-commercial stage biopharmaceutical company with no current revenue. Planning to launch multiple CNS therapies pending FDA approvals for ulixacaltamide (essential tremor) and relutrigine (DEEs). Four late-stage clinical assets carry projected combined revenue potential exceeding $20 billion.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Praxis Precision Medicines product offering

Product offering

Core offering

Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, including essential tremor, developmental and epileptic encephalopathies, focal onset seizures, and generalized epilepsy. The company leverages two proprietary discovery platforms: Cerebrum (small molecule platform for orally available neuronal excitability modulators) and Solidus (antisense oligonucleotide discovery engine). Late-stage drug candidates include ulixacaltamide for essential tremor, relutrigine for SCN2A/SCN8A-DEEs, vormatrigine for focal epilepsy, and elsunersen for SCN2A-DEE.

Product overview

Praxis Precision Medicines is a fully integrated CNS precision neuroscience biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company operates two dedicated technology platforms: Cerebrum (small molecule platform) and Solidus (antisense oligonucleotide platform). The portfolio spans movement disorders and epilepsy, including ulixacaltamide for essential tremor (Phase 3 complete, NDA accepted with January 2027 PDUFA), relutrigine for SCN2A/8A DEEs (Phase 2/3, NDA accepted with September 2026 PDUFA under Priority Review), vormatrigine for focal onset seizures (Phase 2/3), and elsunersen for early onset SCN2A DEE (Phase 1/2). Multiple candidates have received Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from FDA and EMA.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ulixacaltamide Selective T-type calcium channel modulator in development as an oral precision therapy for essential tremor in adults; received FDA Breakthrough Therapy Designation and NDA acceptance with PDUFA target action date of January 29, 2027.
  • Relutrigine Sodium channel functional state modulator for SCN2A- and SCN8A-DEEs and broad developmental and epileptic encephalopathies; received FDA Breakthrough Therapy Designation, Orphan Drug Designation, and Priority Review with PDUFA target action date September 27, 2026.
  • Vormatrigine Sodium channel functional state modulator for focal onset seizures and generalized epilepsy; being evaluated in POWER1 and POWER2 Phase 2/3 trials.
  • Elsunersen (PRAX-222) Gapmer antisense oligonucleotide for early onset SCN2A developmental and epileptic encephalopathy; received FDA Orphan Drug Designation, Rare Pediatric Disease Designation, and Breakthrough Therapy Designation, plus EMA Orphan Drug Designation and Priority Medicines (PRIME) designation.
  • PRAX-020 KCNT1 specific inhibitor small molecule for KCNT1-related conditions including genetic epilepsies.
  • PRAX-080 Gapmer antisense oligonucleotide for PCDH19-related conditions.
  • PRAX-090 Splice switching antisense oligonucleotide for SYNGAP1-related conditions.
  • PRAX-100 Antisense oligonucleotide for SCN2A Autism with undisclosed mechanism.
  • PRAX-050 Movement disorders program with undisclosed mechanism.

Quantifiable outcome

  • 77% sham-adjusted reduction in monthly seizures among pediatric SCN2A-DEE patients (EMBRAVE Part A trial)
  • +4 more outcomes

Companies that use Praxis Precision Medicines

Customer profile

Segments3 records

Ideal customer profiles2 records

Praxis Precision Medicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Praxis Precision Medicines partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • SEQSTERcoreTechnology or Integration · 2 February 2026Expanded partnership with SEQSTER to accelerate clinical trials and data collection in CNS disorders. The collaboration builds on early success in Praxis's Essential3 Program for Essential Tremor, utilizing SEQSTER's 1-Click DataLake technology to expedite CNS disorder trials.
  • SK pharmtecominorOthersPraxis Precision Medicines participated as a speaker and panelist at SK pharmteco's Innovations in Pharmaceutical Manufacturing symposium in Cambridge, Massachusetts, discussing topics including synthetic biology, yeast metabolic engineering, small-molecule scale-up, and stereochemical control.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Praxis Precision Medicines competitors and assessment

Company assessment

Direct peers

  • Sage Therapeutics: Clinical-stage CNS biopharmaceutical company developing therapies for neurological and psychiatric disorders. Most comparable to Praxis given its focus on CNS innovation, late-stage CNS pipeline, and similar pre-commercial profile with a breakthrough-designated asset.
  • Marinus Pharmaceuticals: Specializes in therapeutics for rare seizure disorders, including a recently approved product for CDKL5 deficiency disorder. Directly comparable to Praxis's SCN2A/SCN8A DEE franchise given its rare pediatric epilepsy focus and similar regulatory pathway strategy.
  • PTC Therapeutics: Rare disease biopharmaceutical company with multiple approved products and a CNS franchise. Highly comparable given shared leadership pedigree (Marcio Souza was previously COO), rare disease commercial infrastructure, and small-molecule platform approach.
  • Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotide medicines for genetic diseases, including SCN1A-related Dravet syndrome. Directly comparable given shared focus on ion channelopathies and the Solidus ASO platform approach to CNS genetic epilepsies.

Broad incumbents

  • UCB: Global biopharmaceutical company with a major CNS and epilepsy franchise including multiple approved anti-seizure medications. Comparable as a broad incumbent in the CNS/epilepsy space that Praxis's relutrigine and vormatrigine will compete against commercially.
  • Jazz Pharmaceuticals: Specialty biopharmaceutical company with a significant CNS/epilepsy portfolio including recently acquired products for rare epilepsies. Comparable given its specialty pharma commercial model focused on CNS and rare neurological disorders.
  • Biogen: Major CNS-focused biopharmaceutical company with a portfolio spanning neurology, rare disease, and movement disorders. Comparable as a broad incumbent in CNS with similar strategic emphasis on neurological disease modification.
  • Ionis Pharmaceuticals: Established leader in antisense oligonucleotide drug discovery and development with multiple approved products. Comparable as a broader incumbent in the ASO modality that Praxis's Solidus platform competes with in CNS indications.

Emerging players

  • BridgeBio Pharma: Clinical-stage genetic disease company with programs across rare disorders. Comparable given its genetically driven drug development approach targeting defined patient populations, similar to Praxis's genetic epilepsy strategy.
  • Wave Life Sciences: Clinical-stage genetic medicines company developing oligonucleotide therapies, including programs for CNS disorders such as SCN2A. Directly comparable as an emerging ASO player targeting overlapping CNS genetic epilepsies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Praxis Precision Medicines social profiles

Digital presence

Praxis Precision Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Praxis Precision Medicines leadership team

Management profile

Number of profiles

Profiles19 records

Praxis Precision Medicines funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Praxis Precision Medicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Praxis Precision Medicines

What does Praxis Precision Medicines do?

Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, including essential tremor, developmental and epileptic encephalopathies, focal onset seizures, and generalized epilepsy. The company leverages two proprietary discovery platforms: Cerebrum (small molecule platform for orally available neuronal excitability modulators) and Solidus (antisense oligonucleotide discovery engine). Late-stage drug candidates include ulixacaltamide for essential tremor, relutrigine for SCN2A/SCN8A-DEEs, vormatrigine for focal epilepsy, and elsunersen for SCN2A-DEE.

Is Praxis Precision Medicines a public or private company?

Praxis Precision Medicines is a public company. It is classified as public and is currently operating.

When was Praxis Precision Medicines founded?

Praxis Precision Medicines was founded in 2015. It employs 251 to 500 people.

Where is Praxis Precision Medicines based?

Praxis Precision Medicines is headquartered in Boston, United States, in the North America region.

How does Praxis Precision Medicines make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Praxis Precision Medicines's main competitors?

Direct peers on record are Sage Therapeutics, Marinus Pharmaceuticals, PTC Therapeutics and Stoke Therapeutics. Broad incumbents are UCB, Jazz Pharmaceuticals, Biogen and Ionis Pharmaceuticals. Emerging players are BridgeBio Pharma and Wave Life Sciences.

Does Praxis Precision Medicines have an API?

No public API is recorded for Praxis Precision Medicines.

What industry is Praxis Precision Medicines in?

Praxis Precision Medicines's product category is CNS Therapeutics / Precision Neuroscience Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaPraxis Precision: Steady Hands For A Shaky PDUFA Season (Initiating With A Speculative Buy)The author initiates coverage of Praxis Precision Medicines with a speculative Buy rating and a $410 price target. The stock trades at $316.62, up 3.75%, and the company has a $9.1B market cap.In VivoStrategic Intent: Praxis CEO On “Unlearning,” AI And Launching Two Neuroscience Drugs At OncePraxis Precision Medicines faces two FDA decisions: relutrigine's review extended to Dec. 27, and ulixacaltamide's target date remains Jan. 29, 2027. CEO Marcio Souza emphasizes 'unlearning' assumptions, citing trial design lessons and AI adoption. The company plans to cover 100% of potential relutrigine prescribers from launch.Seeking AlphaPraxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 TranscriptPraxis CEO Marcio Souza discussed the company's pipeline at a UBS conference, highlighting the January 29 PDUFA for ulixacaltamide and 21 programs. He noted 2 NDA approvals pending, with the drug targeting 9 million Americans and many millions globally.TradingViewBaird maintains Praxis Precision Medicine at Outperform, raises price target to $568 from $514Baird maintained Praxis Precision Medicine at Outperform and raised its price target to $568 from $514, a 10.5% increase. The target implies a 73.1% upside from the Nov 13 close of $328.13. Recent analyst price targets range from $189 to $826.TradingViewPRAX: Ulixacaltamide nears its PDUFA as commercial readiness and pipeline catalysts advanceManagement expressed high confidence ahead of Ulixacaltamide's January 29 PDUFA, expecting a broad label and controlled launch. Relutrigine and several pipeline programs offer additional near-term catalysts.Seeking AlphaPraxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)Praxis Precision Medicines reported a Q3 2026 net loss of $94.2 million and held an Investor Day on 12 November. The company's cash balance was $1,233.5 million, and the author restated a fair value of $601 per share, 85% above the stock's 12 November close. The author maintains a Strong Buy rating.Investing.comPraxis outlines launch plans for two drug candidatesPraxis Precision Medicines presented commercial strategies and pipeline updates at its investor day, with FDA PDUFA dates of December 27, 2026 for relutrigine and January 29, 2027 for ulixacaltamide. The company hired about 300 field reps for ulixacaltamide and reported an 86% seizure reduction in relutrigine's EMBOLD study. It plans 2027 studies for ulixacaltamide in Parkinson's, restless legs, and autism.GlobeNewswirePraxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor DayPraxis Precision Medicines hosted its Investor Day, detailing launch readiness for relutrigine and ulixacaltamide with PDUFA dates of December 27, 2026 and January 29, 2027. The company plans to expand ulixacaltamide into Parkinson's disease, restless legs syndrome, and autism spectrum disorder, with studies starting in 2027. It also introduced a broadened pipeline including pain and KCNT1 DEE assets.